Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Randomized, Double-blind, Controlled Phase Ⅰ and Phase Ⅲ Clinical Trial to Evaluate the Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population

NCT06049940 is registered in ClinicalTrials.gov with Sinovac Life Sciences Co., Ltd. as lead sponsor.

NCT NCT06049940
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06049940 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Randomized, Double-blind, Controlled Phase Ⅰ and Phase Ⅲ Clinical Trial to Evaluate the Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population
Lead sponsor
Sinovac Life Sciences Co., Ltd.
Phase
Phase 3
Overall status
Completed
Start date
September 1, 2023
Completion date
March 22, 2024
Enrollment
1,260 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

tetanus